Zami Aberman
2018
In 2018, Zami Aberman earned a total compensation of $592.8K as Co, CEO at Pluristem Therapeutics, a 83% decrease compared to previous year.
Compensation breakdown
| Salary | $524,450 |
|---|---|
| Other | $68,384 |
| Total | $592,834 |
Aberman received $524.5K in salary, accounting for 88% of the total pay in 2018.
Aberman also received $68.4K in other compensation.
Rankings
In 2018, Zami Aberman's compensation ranked 11,326th out of 14,244 executives tracked by ExecPay. In other words, Aberman earned more than 20.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 11,326 out of 14,244 | 21st |
Division Manufacturing | 4,582 out of 5,765 | 21st |
Major group Chemicals And Allied Products | 1,740 out of 2,128 | 18th |
Industry group Drugs | 1,479 out of 1,817 | 19th |
Industry Biological Products, Except Diagnostic Substances | 285 out of 339 | 16th |
Source: SEC filing on April 25, 2019.
Aberman's colleagues
We found two more compensation records of executives who worked with Zami Aberman at Pluristem Therapeutics in 2018.
News
Pluristem Therapeutics CEO Yaky Yanay's 2022 pay falls 86% to $1.3M
February 27, 2023
Pluristem Therapeutics Chairman Zami Aberman's 2020 pay falls 54% to $501K
April 8, 2021
Pluristem Therapeutics Chairman Zami Aberman's 2019 pay jumps 85% to $1.1M
May 20, 2020
Pluristem Therapeutics CEO Zami Aberman's 2018 pay falls 83% to $593K
April 25, 2019